A finding caught my eye, and it’s a good one to think through together, because how we read it matters as much as what it says.

Researchers linked health records with Fitbit data (from the NIH’s All of Us programme) to ask a simple question: when people lose weight on GLP-1 receptor agonists—the class of weight-management medications that includes semaglutide (Wegovy)—do they move more?

The intuition says yes. The data said the opposite. After starting treatment, average daily steps fell from 5,047 to 4,487 (a drop of about 560), and moderate-to-vigorous activity fell from 27.9 to 22.2 minutes a day.

Fascinating and worth holding loosely. It’s an early, real-world signal: a before-and-after look with no comparison group, so it can show movement dropped, but can’t tell us the GLP-1 RAs caused it.

What I take from it isn’t “the drugs make you lazy.” It’s a reminder that weight loss alone doesn’t automatically rebuild healthy habits—and that movement may need to be supported deliberately, not assumed.

Curious what others read into this.
🔗 Endocrine Society press release: https://lnkd.in/gUvTuU7v

Maharjan S, et al. SAT-714 — “Losing Pounds, Not Gaining Steps: The Paradox of GLP-1 Receptor Agonist Therapy.” ENDO 2026, Endocrine Society Annual Meeting, Chicago.